PULSAR radiation plus immunotherapy for advanced abdominal or pelvic tumors
Part of Cancer clinical trials.
This trial tests a special type of radiation called PULSAR combined with an immunotherapy drug (anti-PD-1) in people whose cancer has spread within the abdomen or pelvis. The goal is to see if this combination can shrink tumors and help people live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of cancer that started in the abdomen or pelvis (like liver, kidney, or bladder cancer) and has spread to other places in the body.
- You should have no more than 10 spots of cancer that have spread, and those spots must be safe to treat with radiation.
- You must have at least one tumor that can be measured with scans.
- You must be able to take care of yourself (able to get up and about, though not necessarily able to do heavy work).
- If you have had other cancer in the past 5 years, it must have been a very early, cured kind (like certain skin cancers or early bladder cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of radiation therapy and two immunotherapy drugs (Iparomlimab and Tuvonralimab) for people whose solid tumors have returned or spread and are too large for standard surgery. The goal is to shrink the tumor and control the cancer.
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
This Phase 2 trial tests whether giving targeted radiation and an immunotherapy drug together can control locally recurring rectal cancer in the pelvis. It may help shrink tumors and slow disease growth, especially after certain prior treatments.
This trial tests a combination of radiation therapy, chemotherapy, and immunotherapy given before surgery for rectal cancer that has high-risk features. The goal is to shrink the tumor and improve outcomes for patients with this aggressive form of cancer.
This trial tests combining PULSAR (a type of radiation therapy) with immunotherapy drugs to treat gastric (stomach) cancer that cannot be surgically removed. You must have already completed at least 3 months of chemotherapy with immunotherapy and shown no cancer growth to qualify.
This trial tests a new approach combining a special type of radiation (PULSAR) with immunotherapy and chemotherapy for colorectal cancer that has spread to the liver. The goal is to see if this combination works better than standard treatments.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.